|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-1-28
|
|
pubmed:abstractText |
The combinations of cisplatin-pemetrexed and cisplatin-gemcitabine are considered the standard systemic therapy for malignant pleural mesothelioma (MPM), which is a rapidly progressive tumor. The purpose of the present study is to evaluate the efficacy, safety, and clinical benefit of the gemcitabine plus docetaxel regimen in the second-line treatment of this disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1537-453X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
38-42
|
|
pubmed:meshHeading |
pubmed-meshheading:20142722-Adult,
pubmed-meshheading:20142722-Aged,
pubmed-meshheading:20142722-Aged, 80 and over,
pubmed-meshheading:20142722-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20142722-Bone Neoplasms,
pubmed-meshheading:20142722-Deoxycytidine,
pubmed-meshheading:20142722-Disease Progression,
pubmed-meshheading:20142722-Drug Therapy, Combination,
pubmed-meshheading:20142722-Female,
pubmed-meshheading:20142722-Follow-Up Studies,
pubmed-meshheading:20142722-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:20142722-Humans,
pubmed-meshheading:20142722-Male,
pubmed-meshheading:20142722-Mesothelioma,
pubmed-meshheading:20142722-Middle Aged,
pubmed-meshheading:20142722-Neoplasm Staging,
pubmed-meshheading:20142722-Pleural Neoplasms,
pubmed-meshheading:20142722-Salvage Therapy,
pubmed-meshheading:20142722-Survival Rate,
pubmed-meshheading:20142722-Taxoids,
pubmed-meshheading:20142722-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.
|
|
pubmed:affiliation |
Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens School of Medicine, Greece.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
